In last trading session, Terns Pharmaceuticals Inc (NASDAQ:TERN) saw 1.63 million shares changing hands with its beta currently measuring -0.36. Company’s recent per share price level of $4.13 trading at -$0.06 or -1.43% at ring of the bell on the day assigns it a market valuation of $350.79M. That closing price of TERN’s stock is at a discount of -176.03% from its 52-week high price of $11.40 and is indicating a premium of 2.91% from its 52-week low price of $4.01.

For Terns Pharmaceuticals Inc (TERN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.3 in the current quarter.

Terns Pharmaceuticals Inc (NASDAQ:TERN) trade information

Upright in the red during last session for losing -1.43%, in the last five days TERN remained trading in the red while hitting it’s week-highest on Thursday, 02/13/25 when the stock touched $4.13 price level, adding 5.28% to its value on the day. Terns Pharmaceuticals Inc’s shares saw a change of -25.45% in year-to-date performance and have moved -4.84% in past 5-day. Terns Pharmaceuticals Inc (NASDAQ:TERN) showed a performance of -7.19% in past 30-days.

Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 79.35% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 26. It follows that stock’s current price would drop -142.13% in reaching the projected high whereas dropping to the targeted low would mean a loss of -142.13% for stock’s current value.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.40% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 6.27% while estimates for its earnings growth in next 5 years are of -4.53%.

Terns Pharmaceuticals Inc (NASDAQ:TERN)’s Major holders

ORBIMED ADVISORS LLC is the top institutional holder at TERN for having 7.62 million shares of worth $51.89 million. And as of 2024-06-30, it was holding 10.2326 of the company’s outstanding shares.

The second largest institutional holder is VIVO CAPITAL, LLC, which was holding about 6.18 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.3038 of outstanding shares, having a total worth of $42.11 million.